Press release
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,
About this update from Ocugen, Inc.
[{"type":"text","content":"MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston, Mass. PresentationSession: Gaining a Deeper Understanding of the Underlying Causes of Dry AMD to Inform Therapeutic Drug Development and Target SelectionTopic: Understanding the Complexity of Dry AMD: A Multifactorial PerspectiveDate: November 16, 2023Time: 11 – 11:30 a.m. ET OCU410, Ocugen’s modifier gene therapy candidate utilizing the nuclear hormone receptor gene RORA, is currently being developed for the treatment of geographic atrophy—an advanced form of dry age-related macular degeneration affecting approximately 1 million people in the United States alone. The Company is enthusiastic about the potential for OCU410 to address unmet medical need in this category and intends to dose patients in the Phase 1/2 trial by the end of 2023. About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “sho...